196 related articles for article (PubMed ID: 23478936)
1. Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease.
Tokushige K; Hashimoto E; Kodama K; Tobari M; Matsushita N; Kogiso T; Taniai M; Torii N; Shiratori K; Nishizaki Y; Ohga T; Ohashi Y; Sato T
J Gastroenterol; 2013 Dec; 48(12):1392-400. PubMed ID: 23478936
[TBL] [Abstract][Full Text] [Related]
2. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease.
Charlton M; Angulo P; Chalasani N; Merriman R; Viker K; Charatcharoenwitthaya P; Sanderson S; Gawrieh S; Krishnan A; Lindor K
Hepatology; 2008 Feb; 47(2):484-92. PubMed ID: 18220286
[TBL] [Abstract][Full Text] [Related]
3. Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease.
Caussy C; Ajmera VH; Puri P; Hsu CL; Bassirian S; Mgdsyan M; Singh S; Faulkner C; Valasek MA; Rizo E; Richards L; Brenner DA; Sirlin CB; Sanyal AJ; Loomba R
Gut; 2019 Oct; 68(10):1884-1892. PubMed ID: 30567742
[TBL] [Abstract][Full Text] [Related]
4. Concomitant nonalcoholic fatty liver disease does not alter the activity, severity or course of primary biliary cholangitis.
Minuk GY; Iliant V; Zhou N; Kaita KD; Wong SG; Peretz D; Uhanova J
Liver Int; 2018 Jun; 38(6):1110-1116. PubMed ID: 29193593
[TBL] [Abstract][Full Text] [Related]
5. Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis.
Masarone M; Troisi J; Aglitti A; Torre P; Colucci A; Dallio M; Federico A; Balsano C; Persico M
Metabolomics; 2021 Jan; 17(2):12. PubMed ID: 33458794
[TBL] [Abstract][Full Text] [Related]
6. Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease.
Moylan CA; Pang H; Dellinger A; Suzuki A; Garrett ME; Guy CD; Murphy SK; Ashley-Koch AE; Choi SS; Michelotti GA; Hampton DD; Chen Y; Tillmann HL; Hauser MA; Abdelmalek MF; Diehl AM
Hepatology; 2014 Feb; 59(2):471-82. PubMed ID: 23913408
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients.
Koehler E; Swain J; Sanderson S; Krishnan A; Watt K; Charlton M
Liver Int; 2012 Feb; 32(2):279-86. PubMed ID: 22098614
[TBL] [Abstract][Full Text] [Related]
8. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease.
Murphy SK; Yang H; Moylan CA; Pang H; Dellinger A; Abdelmalek MF; Garrett ME; Ashley-Koch A; Suzuki A; Tillmann HL; Hauser MA; Diehl AM
Gastroenterology; 2013 Nov; 145(5):1076-87. PubMed ID: 23916847
[TBL] [Abstract][Full Text] [Related]
9. Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease.
Barr J; Vázquez-Chantada M; Alonso C; Pérez-Cormenzana M; Mayo R; Galán A; Caballería J; Martín-Duce A; Tran A; Wagner C; Luka Z; Lu SC; Castro A; Le Marchand-Brustel Y; Martínez-Chantar ML; Veyrie N; Clément K; Tordjman J; Gual P; Mato JM
J Proteome Res; 2010 Sep; 9(9):4501-12. PubMed ID: 20684516
[TBL] [Abstract][Full Text] [Related]
10. NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD.
Demir M; Lang S; Schlattjan M; Drebber U; Wedemeyer I; Nierhoff D; Kaul I; Sowa J; Canbay A; Töx U; Steffen HM
PLoS One; 2013; 8(3):e58360. PubMed ID: 23555578
[TBL] [Abstract][Full Text] [Related]
11. Platelet count for predicting fibrosis in nonalcoholic fatty liver disease.
Yoneda M; Fujii H; Sumida Y; Hyogo H; Itoh Y; Ono M; Eguchi Y; Suzuki Y; Aoki N; Kanemasa K; Imajo K; Chayama K; Saibara T; Kawada N; Fujimoto K; Kohgo Y; Yoshikawa T; Okanoue T;
J Gastroenterol; 2011 Nov; 46(11):1300-6. PubMed ID: 21750883
[TBL] [Abstract][Full Text] [Related]
12. A metabolomics approach to the validation of predictive metabolites and phenotypic expression in non-alcoholic fatty liver disease.
Ganesan R; Gupta H; Jeong JJ; Sharma SP; Won SM; Oh KK; Yoon SJ; Kim DJ; Suk KT
Life Sci; 2023 Jun; 322():121626. PubMed ID: 37003543
[TBL] [Abstract][Full Text] [Related]
13. Association between noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver disease.
Sesti G; Fiorentino TV; Arturi F; Perticone M; Sciacqua A; Perticone F
PLoS One; 2014; 9(2):e88569. PubMed ID: 24520400
[TBL] [Abstract][Full Text] [Related]
14. Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD.
Caussy C; Hsu C; Singh S; Bassirian S; Kolar J; Faulkner C; Sinha N; Bettencourt R; Gara N; Valasek MA; Schnabl B; Richards L; Brenner DA; Hofmann AF; Loomba R
Aliment Pharmacol Ther; 2019 Jan; 49(2):183-193. PubMed ID: 30506692
[TBL] [Abstract][Full Text] [Related]
15. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
[TBL] [Abstract][Full Text] [Related]
16. Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity.
Di Mauro S; Scamporrino A; Petta S; Urbano F; Filippello A; Ragusa M; Di Martino MT; Scionti F; Grimaudo S; Pipitone RM; Privitera G; Di Pino A; Scicali R; Valenti L; Dongiovanni P; Fracanzani A; Rabuazzo AM; Craxì A; Purrello M; Purrello F; Piro S
Liver Int; 2019 Sep; 39(9):1742-1754. PubMed ID: 31169972
[TBL] [Abstract][Full Text] [Related]
17. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population.
Sumida Y; Yoneda M; Hyogo H; Itoh Y; Ono M; Fujii H; Eguchi Y; Suzuki Y; Aoki N; Kanemasa K; Fujita K; Chayama K; Saibara T; Kawada N; Fujimoto K; Kohgo Y; Yoshikawa T; Okanoue T;
BMC Gastroenterol; 2012 Jan; 12():2. PubMed ID: 22221544
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD).
Yoneda M; Yoneda M; Mawatari H; Fujita K; Endo H; Iida H; Nozaki Y; Yonemitsu K; Higurashi T; Takahashi H; Kobayashi N; Kirikoshi H; Abe Y; Inamori M; Kubota K; Saito S; Tamano M; Hiraishi H; Maeyama S; Yamaguchi N; Togo S; Nakajima A
Dig Liver Dis; 2008 May; 40(5):371-8. PubMed ID: 18083083
[TBL] [Abstract][Full Text] [Related]
19. Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolome.
Moolla A; de Boer J; Pavlov D; Amin A; Taylor A; Gilligan L; Hughes B; Ryan J; Barnes E; Hassan-Smith Z; Grove J; Aithal GP; Verrijken A; Francque S; Van Gaal L; Armstrong MJ; Newsome PN; Cobbold JF; Arlt W; Biehl M; Tomlinson JW
Aliment Pharmacol Ther; 2020 Jun; 51(11):1188-1197. PubMed ID: 32298002
[TBL] [Abstract][Full Text] [Related]
20. Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease.
Yang M; Jiang L; Wang Y; Li X; Zou Z; Han T; Nan Y; Lu F; Zhao J
J Gastrointestin Liver Dis; 2019 Sep; 28(3):289-296. PubMed ID: 31517325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
